Editorial: Insights in obesity: 2023

Editorial: Insights in obesity: 2023

Saved in:

Bibliographic Details
Main Author:	Katsunori Nonogaki
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-11-01
Series:	Frontiers in Endocrinology
Subjects:	obesity GLP-1 GIP semaglutide stigma inheritance
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2024.1489087/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence
by: Srikanth Krishnan, et al.
Published: (2025-01-01)

Tirzepatide - role in obesity, health and physical wellness. Information overview
by: Anna Hanslik, et al.
Published: (2025-02-01)

A GLP-1 analogue optimized for cAMP-biased signaling improves weight loss in obese mice
by: Jonathan D. Douros, et al.
Published: (2025-10-01)

Glucose-dependent insulinotropic polypeptide (GIP)
by: Timo D. Müller, et al.
Published: (2025-05-01)

Tirzepatide – a new hope for type 2 diabetes mellitus and obesity management. A literature review.
by: Izabela Stawicka, et al.
Published: (2024-11-01)

Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity
by: Andrew Overholser, et al.
Published: (2025-02-01)

Semaglutide, liraglutide and tirzepatide: Comparison of effectiveness in the treatment of obesity – a literature review
by: Karolina Baran, et al.
Published: (2024-12-01)

PANCREATIC AND EXTRA-PANCREATIC EFFECTS OF INCRETINS AND PERSPECTIVES FOR STUDYING ENTEROINSULIN HORMONAL SYSTEM DURING GESTATIONAL DISORDER OF CARBOHYDRATE METABOLISM
by: T. V. Saprina, et al.
Published: (2013-06-01)

Heart failure with preserved ejection fraction and obesity: emerging metabolic therapeutic strategies
by: Wenwen Zheng, et al.
Published: (2025-08-01)

Specific loss of GIPR signaling in GABAergic neurons enhances GLP-1R agonist-induced body weight loss
by: Jordan Wean, et al.
Published: (2025-05-01)

Editorial: Incretin-based therapies in the treatment of metabolic syndrome: expanding roles beyond weight management
by: Kexin Zhang, et al.
Published: (2025-08-01)

Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado
by: Michael J. DiStefano, et al.
Published: (2025-12-01)

Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
by: Rui Salvador, et al.
Published: (2025-03-01)

A review: Anti-obesity drug discovery from natural plant metabolites and endogenous peptides
by: Xiaomu Zhu, et al.
Published: (2024-01-01)

Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland
by: Hoffmann K, et al.
Published: (2025-08-01)

Efficacy and Safety of Tirzepatide for Weight Management in Non-Diabetic Obese Individuals: A Narrative Review
by: Mohammed Sallam, et al.
Published: (2025-04-01)

Role of physical activity in GLP-1 receptor agonist therapy for obesity treatment
by: Łukasz Zdziebkowski, et al.
Published: (2025-07-01)

Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review
by: Aleksander Jentkiewicz, et al.
Published: (2025-02-01)

Efficacy and Safety of Tirzepatide in the Treatment of Obesity in Adults: A Comprehensive Review
by: Karolina Skonieczna, et al.
Published: (2025-05-01)

Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review
by: Andrijana Koceva, et al.
Published: (2025-01-01)

Incretin-Based Therapies and Cancer: What’s New?
by: Sanja Medenica, et al.
Published: (2025-04-01)

Oral semaglutide for the treatment of obesity: a retrospective real-world study
by: Mitja Krajnc, et al.
Published: (2025-05-01)

The postprandial dynamics of gastroduodenal zone hormones in patients with metabolic obesity associated or not associated with type 2 diabetes
by: Elena Vital'evna Kirienkova, et al.
Published: (2015-12-01)

Addressing the Shortage of GLP-1 RA and Dual GIP/GLP-1 RA-Based Therapies—A Systematic Review
by: Velimir Altabas, et al.
Published: (2025-06-01)

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Evolving Insights into Pathogenesis, Progression, and Personalized Treatment Approaches
by: Paweł Kukiełka, et al.
Published: (2025-07-01)

Effects of Semaglutide and Tirzepatide on Bone Metabolism in Type 2 Diabetic Mice
by: Fang Lv, et al.
Published: (2024-12-01)

Effect of high intakes of protein-only and carbohydrate-only on plasma metabolites and hormones, in addition to nitrogen excretion
by: Matthieu Clauss, et al.
Published: (2025-08-01)

Effect of GIP and GLP-1 infusion on bone resorption in glucose intolerant, pancreatic insufficient cystic fibrosis
by: Wang Shin Lei, et al.
Published: (2025-06-01)

Individualized virtual integrative medicine (IVIM): A clinical model for enhanced GLP-1 therapeutic outcomes
by: Jessica Duncan, et al.
Published: (2025-09-01)

Semaglutide reverses the chronic myopathy of hyperkalemic periodic paralysis: a case report
by: Kenneth Brand, et al.
Published: (2025-04-01)

Semaglutide and human reproduction: caution at the intersection of energy balance, ovarian function, and follicular development
by: E. Scott Sills, et al.
Published: (2025-08-01)

Revisiting the role of novel weight management medications and bariatric surgery
by: LIANG Hui
Published: (2025-06-01)

The Impact of GLP-1 Receptor Agonists on Women's Reproductive Health: A Review
by: Marta Wolszczak, et al.
Published: (2025-06-01)

Corticosteroid Administration Enhances the Glycemic, Insulinemic, and Incretin Responses to a High‐Protein Mixed Meal in Adult Horses
by: Allison T. Palmer, et al.
Published: (2025-03-01)

Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review
by: Juliana West, et al.
Published: (2025-04-01)

Contractile Effects of Semaglutide in the Human Atrium
by: Joachim Neumann, et al.
Published: (2024-08-01)

Tirzepatide-induced lichen planus pigmentosus
by: Craig M. Fisher, MD, et al.
Published: (2025-05-01)

Utilization Trends of Dual GIP/GLP-1 Receptor Agonist, Newer Glucose-Lowering Medications, and Anti-Obesity Medications Among Patients With Chronic Kidney Disease With and Without Type 2 Diabetes
by: Panupong Hansrivijit, et al.
Published: (2025-06-01)

Efficacy and safety of once-weekly semaglutide monotherapy in a young subject with Prader-Willi syndrome, obesity, and type 2 diabetes: a case report
by: Elisa Dinoi, et al.
Published: (2025-02-01)

The first generic tirzepatide GP30931: physicochemical and biological similarity to the reference drug
by: I. A. Lugovik, et al.
Published: (2025-06-01)